Abstract The novel ability to quantify drug and tracer concentrations in vivo by optical means leads to the possibility of detecting and quantifying blood brain barrier (BBB) disruption in real-time by monitoring concentrations of chromophores such as Evan's Blue. In this study, experiments were conducted to assess the disruption of the BBB, by intraarterial injection of mannitol, in New Zealand white rabbits. Surgical preparation included: tracheotomy for mechanical ventilation, femoral and selective internal carotid artery (ICA) catheterizations, skull screws for monitoring electrocerebral activity, bilateral placement of laser Doppler probes and a small craniotomy for the placement of a fiber optic probe to determine tissue Evan's Blue dye concentrations. Evans Blue (6.5 mg/kg) was injected intravenously (IV) just before BBB disruption with intracarotid mannitol (25%, 8 ml/40 s). Brain tissue concentrations of the dye in mannitol-treated and control animals were monitored using the method of optical pharmacokinetics (OP) during the subsequent 60 min. Hemodynamic parameters, heart rate, blood pressure, and EKG remained stable throughout the experiments in both the control and the mannitol-treated group. Brain tissue concentrations of Evan's Blue and the brain:plasma Evan's Blue partition coefficient progressively increased during the period of observation. A wide variation in brain tissue Evan's Blue concentrations was observed in the mannitol group. The experiments demonstrate the feasibility of measuring tissue concentrations of Evan's Blue without invading the brain parenchyma, and in real-time. The data suggest that there are significant variations in the degree and duration of BBB disruption induced with intraarterial mannitol. The ability to optically monitor the BBB disruption in real-time could provide a feedback control for hypertonic disruption and/or facilitate dosage control for chemotherapeutic drugs that require such disruption.
Introduction
Safe, effective, and predictable disruption of the blood brain barrier (BBB) is a key step in the delivery of certain chemotherapeutic drugs, as well as nanoparticles, liposomes, and viral vectors-the current and future therapies for brain tumors and a range of other brain diseases [1] . BBB has been a major hurdle for the delivery of drugs to brain tissue [2] . The barrier seems to be far more complex and dynamic than perceived in the past. A variety of methods and drugs have been employed to disrupt the barrier and improve drug delivery [3] [4] [5] [6] . However, for the last three decades intraarterial mannitol has remained the main clinical method for transient disruption [7] . Limited clinical data from human subjects also shows that the degree of disruption, and subsequent concentrations of drugs in the cerebrospinal fluid, vary considerably after mannitol administration, Fig. 1 [8] . Many alternatives to mannitol have evolved over that time but none has found wide clinical application yet. Disruption of BBB with intracarotid mannitol is reasonably safe and its effectiveness is well supported by anecdotal evidence [9, 10] . Significant complications have also been reported during the procedure and radiological verification of BBB disruption is often needed during clinical procedures, often after the delivery of chemotherapeutic drugs [11, 12] .
The osmotic disruption of the BBB is affected by a number of factors, Table 1 [13] . Variations in BBB disruption could have a profound impact on the regional delivery of chemotherapeutic drugs. Inadequate disruption could lead to failure of treatment, while severe disruption could lead to seizures or even fatal brain edema [11] . The ability to quantity drug and tracer concentrations in vivo using the method of optical pharmacokinetics, a variation of diffuse reflectance spectroscopy, leads to the possibility of detecting and quantifying blood-brain-barrier disruption in vivo in real-time [14] [15] [16] [17] [18] . Optical detection of drug concentrations requires the drug to have a chromophore absorption band whose spectrum is sufficiently distinct from those of oxyhemoglobin and deoxyhemoglobin. The absorbance spectrum of Evan's Blue lends well to such measurements. Evan's Blue (MW 980 Da) is a water-soluble dye that is traditionally used to demonstrate the opening of the BBB.
Our hypothesis was that it is feasible to track disruption of the BBB by monitoring tissue concentrations of Evan's Blue. Furthermore, variations in BBB disruption will have a profound impact on the magnitude and rate of Evan's Blue uptake.
Methods
We tested our hypothesis in anesthetized New Zealand white rabbits, which have a primate-like separation of internal (ICA) and external carotid arteries and are sufficiently large to safely permit required instrumentation and monitor the physiologic parameters. The protocol was approved by the Institutional Animal Care and Use Committee. Animals had free access to food and water prior to experiments. In the past, we had observed great variability in BBB disruption after intracarotid mannitol injection in our rabbit model [19] . Subsequently, we eliminated the potential confounders, such as the empirical use of steroids, varying depth of anesthesia, temperature, method of injection, and preparation of mannitol. We took meticulous care in isolating the ICA and standardizing the dose response characteristics in each animal experiment [20] . Yet, the variability persisted in the preliminary studies, Fig. 2a-c .
Surgical preparation was undertaken under intramuscular ketamine sedation with intravenous propofol anesthesia, which was supplemented by infiltration of the incision sites with a long acting local anesthetic agent, bupivacaine. The preparation included: tracheotomy for mechanical ventilation aimed at an end tidal CO 2 of 30-40 mmHg, femoral Fig. 1 Variation in blood brain barrier disruption (BBBD) by intraarterial mannitol 3-11 ml/s for 30 s in human subjects. There is a 109 variation in the degree of barrier opening as judged by CT imaging, Hounsfield Units (DHU). There is also a 10-259 variation in CSF concentrations of methotrexate (MTX) that is more pronounced with vertebral injections than with carotid injections [8] .
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Anesthetic drugs [13, 29] Time elapsed [10, 47] Nitric oxide [48, 49] Criteria [50] and selective ICA catheterizations, skull screws for monitoring electrocerebral activity, bilateral placement of laser Doppler probes and a small craniotomy for placement of the OP fiberoptic probe to measure tissue Evan's Blue concentration over the parietal cortex. EEG activity was carefully monitored and propofol infusion was targeted to low-frequency, high-amplitude activity of about 100-200 lV, interspersed with low-amplitude, high-frequency activity. The esophageal temperature was maintained at 36-37°C. Intravenous fluids were administered at a rate of 20 ml/kg/h and consisted of a mixture of lactated Ringer's solution, 5% albumin, and 5% dextrose in a ratio of 3:1:1. Oxygen saturation and EEG activity were monitored in real-time. This experimental protocol ensures stable hemodynamics, and the preparation can withstand fairly severe hemodynamic stresses [21] . Considerable precautions were taken to ensure correct isolation of the ICA, which exhibits considerable variation in the anatomy for this species [22] . Therefore, it is necessary to correctly isolate the artery and establish a dose response prior to experimental drug delivery. Two operators with sufficient experience confirmed the origin of the ICA. On identification, the ICA was isolated from all other arterial branches using an atraumatic arterial clip. Next, a 0.5-ml saline bolus was injected to demonstrate a blanching of the retinal vessels, thus verifying catheter placement [23] . Later, the animal was secured to the stereotactic frame, and laser Doppler probes were placed on the skull. Then 0.25 ml of saline was injected to see if the vessel was correctly isolated, causing an abrupt decrease in blood flow, as sensed by both of the laser Doppler probes [20] . Finally, 0.4 ml of propofol was injected, producing a short period of electrocerebral quiescence for 5-10 s, if the saline injection produced a questionable decrease in laser Doppler blood flow, which is consistent with an effective delivery of 2 mg of the drug [24] . Collectively all these tests assured the correct isolation of the artery in all animals.
Optical pharmacokinetics (OP), a variation of diffuse reflectance spectroscopy, is a non-invasive, real-time method that was developed to non-invasively measure concentrations of chromophores in turbid media [24] . Briefly, as implemented here, a pulsed xenon-arc lamp is used as a broadband illumination light source. A fiber optic probe, with separate source and detector fibers, with its tip placed gently in direct contact with the dura, is used to collect absorption spectra of Evan's Blue over time from the tissue beneath. Determination of the Evan's Blue concentration is accomplished by using a modified Beer's Law to derive the total absorption coefficient change, from spectra measured before and after Evan's Blue administration. The tissue volume that is sampled is approximately 3 9 3 mm in area, to a depth of approximately 3 mm.
The experimental preparation was allowed to recover for 15 min. Over the fronto-parietal cortex, a small area of the skull flap was removed, and the optical fiber probe was placed in contact with the dura. Wetting the surface with saline provided reliable optical contact between the fiber tip and the dura. Figure 3 shows the sequence of the experiment.
Measurements before the Evan's Blue dye administration, baseline optical data, were collected for 1 min at a rate of 12 spectra/min. For each animal the number of integrated light pulses was adjusted to obtain adequate optical signal in the 450-900 nm range. (A single spectral measurement takes 100-300 ms.) After acquisition of the baseline spectra, the rate of data acquisition was increased to obtain 300 spectra every 0.5 s. Concurrent with the start of the higher data acquisition rate, Evan's Blue (6.5 mg/kg) was injected intravenously as a 0.2% solution at a rate of 6 ml/min. Approximately 30 s after completing the infusion (approximately 1 min after start of Evan's Blue infusion), intraarterial mannitol 25% was infused at a rate of 8 ml/40 s. The tissue concentration of Evan's Blue was monitored over the next hour, acquiring spectra every 10 s. Overall, 612 measurements were obtained in each animal over a period of approximately 60 min. The slight variability was due to the differences in the duration of the light pulse necessary to obtain an optimum spectrum that varied between animals.
Hemodynamic data, blood pressure, and EEG activity were recorded at a frequency of 200/s. Representative data were analyzed at six time points: (i) baseline; (ii-vi) 1, 5, 15, 30 and 60 min after mannitol injection. Heparinized blood samples, for the determination of plasma Evan's Blue concentrations, were taken before and immediately after mannitol injection, then 5, 15, 30 and 60 min thereafter. To determine plasma Evan's Blue concentrations, a 1-ml sample of arterial blood was centrifuged at 12,000 rpm for 15 min, the supernatant was diluted in formamide (1:10,000), and the concentration was optically measured by a spectrophotometer in batches of up to 48 samples per run. Paired samples were analyzed to assess the consistency of measurements. A control Evan's Blue dilution curve was determined to convert the absorbance values to plasma Evan's Blue concentrations for each run. The animals were euthanized 60 min after injection of mannitol, and brain tissue was harvested for postmortem examination for each animal. Data analysis: As indicated above, the data were collected at six time points for each challenge: baseline, 1 min after mannitol or 2 min after Evan's Blue, 5, 15, 30 and 60 min after mannitol. Within each group (mannitol and control), data at the six time points were analyzed by repeated measures ANOVA. Across the groups (control and mannitol), data were analyzed by factorial ANOVA. A Bonferroni-Dunn post-hoc test was used for multiple comparisons. A P value of \0.0033 was deemed good for repeat measurements, while a P value of \0.05 was considered significant between the two groups.
Results
Twenty-three New Zealand white rabbits were randomly assigned to two groups: control (n = 13) and mannitol (n = 10) groups. Persistent bleeding in one case, and noisy data due to movements of the probe relative to the head, resulted in data artifacts that prevented further analysis for two animals in the mannitol group and one in the control group. Therefore, data from 11 controls and 9 mannitol treated animals was available for the final analysis.
The hemodynamic and cerebral vascular effects of mannitol injection were assessed as follows: the baseline weight, heart rate, mean arterial pressure, end-tidal carbon dioxide concentrations, respiratory rate, temperature and oxygen saturation were comparable in the two groups. Most physiological parameters remained stable during the study. There was an increase in CBF lasting for 5 min with the injection of mannitol, which is typical. As expected, injection of Evan's Blue perturbed measurement of the oxygen saturation due to the interference of the dye with pulse oximeter measurements (see Table 2 ). The saturation decreased nearly to the lowest level recordable by the oximeter (70%) after Evan's Blue injection. 
Plasma concentrations
The injection of Evan's Blue led to a similar initial increase in plasma concentrations of the dye for both groups. However, there was significant difference in plasma concentrations of Evan's Blue between the control and the mannitol groups 5-60 min after the injection of the dye as seen in Fig. 4a .
Tissue concentrations
Concentrations of Evan's Blue in brain tissue increased progressively in the mannitol group over time, Fig. 4b . The tissue concentrations of Evan's Blue after the disruption of the BBB were 6 times the control values at the end of 60 min. A small progressive rise in tissue concentrations of Evan's Blue was also seen in the control group.
Brain: plasma Evan's Blue ratio
The calculated partition ratio between brain and plasma Evan's Blue concentrations showed a progressive increase over time as seen in Fig. 4c . Large variation was seen in the tissue Evan's Blue concentrations after intraarterial mannitol (2.9-76.18 lg/ml), and the range of the brain:-plasma partition coefficient (0.012-0.46) at 60 min was larger than the range of the corresponding values in the control group: (1.77-8.59 lg/ml). Figures 5 and 6 illustrate the two extreme examples of EB uptake after BBBD in this study. The peak EB concentration in Fig. 6 was 76.18 lg/ ml that was almost 20-fold higher than in peak concentration in Fig. 5, 3 .5 lg/ml.
Discussion
Disruption of the BBB is a critical step in the delivery of a variety of chemotherapeutic drugs. This study shows that it is possible to track tissue concentration of a marker for BBB disruption (Evan's Blue), in real-time using optical pharmacokinetics. The major finding of this study was that BBB can be disrupted by intraarterial mannitol; however, the severity of disruption is inconsistent. Mannitol had been widely used in clinical setting, and we decided to investigate this application first. It is generally accepted that the inconsistency of disruption is a consequence of physiological variation, and a variety of other factors, Table 1 . Although this finding by itself is not novel, to our best knowledge, this is the first report describing the use of tissue noninvasive optical technology to track BBB disruption.
The current clinical method of BBB disruption uses angiographic determination of the rate of mannitol injection. Intraarterial mannitol is injected at a rate that is the minimal rate for the contrast to reflux into the feeding artery [10] . This rate of injection varies from 3-11 ml/s. To Table 2 Physiological changes in control (n = 11) and mannitol (n = 9) treatment groups effectively disrupt the BBB the rate must be maintained for at least 30 s. The volume of mannitol required in human subjects varies from 90 to 330 ml [8] . In the rabbit a volume of 8 ml/40 s has been recommended for disrupting the BBB [19, 23] . While we did not undertake angiographic measurements, we observed that the CBF as measured by laser Doppler transiently decreased to near zero during mannitol infusion (see Figs. 5, 6), suggesting that the rate of mannitol infusion was sufficient to transiently overwhelm the CBF in our model by displacing blood.
Immediately after mannitol injection, we observed a rebound increase in blood flow. The hyperemic response lasted for 5-10 min. We did not observe any consistent change in blood pressure or in the heart rate. In both the mannitol and the control groups, the heart rate showed a progressive, though statistically insignificant, increase over time. Hypertension, bradycardia and arrhythmias have been reported during clinical disruption of the BBB with intraarterial mannitol. We occasionally observed a hypertensive response, but overall hemodynamic changes were not statistically significant. We frequently observed attenuation of EEG activity to the point of silence, often followed by a persistent loss of high frequency EEG activity after mannitol injection. The use of EEG to detect BBB disruption needs to be assessed in future studies.
Evan's Blue is a classical marker of BBB disruption. The traditional dose of plasma Evan's Blue used for determining BBB disruption in rabbits can be as high as 25-90 mg/kg which produces intense blue coloration of the brain tissue that can be visually assessed [25, 26] . However, this dose of Evan's Blue does not reflect the subtle concentrations of chemotherapeutic drugs and can overwhelm optical measurements. We therefore employed a much smaller dose of Evan's Blue, 6.5 mg/kg, which was sufficient to be detected by the OP method, yet remained discernable to the eye for the post-mortem tissue, Fig. 6 .
The plasma Evan's Blue concentrations were comparable 1 min after mannitol injection but showed two distinct trends. Although the plasma concentration remained stable in each group, over time a significant difference emerged between mannitol treated and the control group. Since Evan's Blue binds to plasma proteins and its clearance from the central compartment is slow due to a slow uptake by tissues, plasma Evan's Blue concentrations provide a measure of plasma volume. We suspect that the increase in concentrations of Evan's Blue over time could be due to diuresis by mannitol and a contraction of the plasma volume.
Optically measured brain tissue concentrations of Evan's Blue increased progressively after mannitol injection by a factor 2 at 5 min, increasing to a factor 5 at 1 h. This indicates a progressive tissue uptake of Evan's Blue after BBB disruption. A small (25%) increase in tissue concentration of Evan's Blue was evident in the controls and could reflect non-specific uptake of Evan's Blue at the site of optical probe placement. Some injury in the preparation is likely to occur when the skull flap is removed. The removal of the bone flap is often complicated by its adherence to the dura, as well as the potential injury that could occur from the vibrations of the surgical drill.
Although optical measurements are generally taken through the inner table of the skull, in this particular study the measurements were made through the dura to improve the signal-to-noise ratio, which was initially thought to be necessary with the decrease in the dose of Evan's Blue. Due to the trend of plasma concentrations to increase in the mannitol group and decrease in the control group, we also assessed the brain:plasma Evan's Blue partition coefficient. The tissue partition coefficient also progressively increased over time and was three times higher in the mannitol group.
The results that show a progressive increase in Evan's Blue tissue concentration suggest that the BBB remains open for at least an hour after mannitol injection. In human clinical studies the peak CSF concentration did not occur until 8-10 h after mannitol injection. The increase in CSF concentrations was believed to be due to the release of the drug from the brain parenchyma into the CSF rather than the sustained opening of the BBB [8] . It is generally believed that mannitol only transiently disrupts the BBB. This, however, may not always be the case. For example, in rodents the BBB remained opened for 6 h after mannitol injection [10] .
The BBB is often assumed to be a simple tissue membrane rather than a complex regulatory system. Considering the dynamic nature and the multitude of complex processes that determine the transport of substances across the barrier, it is a reasonable assumption that a number of factors affect the duration and the degree of BBB disruption. The ability to optically track brain-tissue tracer concentrations can help us understand these factors. For example, in Figs. 5 and 6, we see two different patterns of tracer uptake after BBB disruption. In one case the tissue concentration of Evan's Blue progressively increases and follows a saturation pattern, whereas, in the other case, there is minimal early uptake of the Evan's Blue, but the concentrations do not increase over time. This suggests that in the first case, the BBB remained open for at least an hour while in the other case, it opened only transiently, if at all. Furthermore, we observed a wide range of tissue Evan's Blue concentrations (and brain: plasma partition coefficient) after BBB disruption, reflecting the different degrees of BBB disruption with intraarterial mannitol.
Variability of BBB disruption has been attributed to a number of factors. Regional variations in BBB disruption are often seen in different arterial distributions; e.g., a close examination of the data in Fig. 1 reveals that for a given degree of disruption of the BBB, the CSF concentrations of methotrexate were higher with vertebral artery injection when compared to carotid injection [8] . The difference could be due to the increased transport across the choroid plexuses or to a more prolonged BBB disruption with vertebral artery injections. It is generally believed that the BBB of malignant tumors is more sensitive to disruption, or is already disrupted for angiogenic microvessels [27] . Hypothermia [28] , hypercapnia [13] and background anesthesia also affect the hypertonic disruption of the BBB, Table 1 . While hypothermia and hypercapnia protect the BBB, hyperthermia and hypocapnia do not. Volatile anesthetic agents, such as methoxyflurane, sometimes isoflurane, and narcotics attenuate BBBD, while anesthetic agents, like ketamine and thiopental, augment the disruption [29, 30] . Intravenous propofol does not adversely affect BBBD [10] .
Over the years a number of alternatives to mannitol have been proposed, and some of them seem superior to mannitol in preclinical testing. They include osmotic agents like arabinose [31] , contrast agents like Optison [32] , and bradykinin analogues like RMP-7 (Cereport) [3] . [However, none of them has been accepted in clinical practice. Optical measurements could help compare the efficacy of these agents with that of mannitol. Current intraarterial chemotherapy regimens for brain tumors use a fixed angiographically determined dose of mannitol and predetermined doses of chemotherapeutic drugs. The disruption of the BBB is usually assessed by injection of contrast agents within 5-90 min of mannitol injection [8, [10] [11] [12] . Most contrast agents used for X-ray or magnetic resonance imaging have potentially neurotoxic effects. As many as 25% of patients who undergo BBB disruption present with focal seizures that are, in part, due to the use of contrast for imaging purposes [11] . Overall there are concerns regarding the safety and efficacy of BBB disruption [10] . In experienced hands, the procedure is safe and effective. Although effort has been made to improve the consistency of the technique, it is still available in only a handful of centers.
Translating our results to human subjects is theoretically possible by the use of clinical near-infrared spectroscopic devices with tracers like indocyanine green [29] . NIRS optical grids with combinations of several emitter and receiving fibers that can monitor changes in tissue spectrum over large cortical zones could provide a better quantification of BBB disruption [33] . Given the larger scale of human heads, such devices can be used through the intact scalp and skull. There are many advantages in developing optical technologies to monitor BBB disruption. Optical feedback during BBB disruption could help to determine if there was any need to disrupt the barrier, as the blood:tumor barrier might already be permeable in a given patient, to determine the dose of mannitol, alter the dose of chemotherapeutic drugs based on the degree of BBB disruption, predict complications, and avoid the use of radiocontrast agents.
In conclusion, we show the feasibility of real-time monitoring of BBB disruption by quantifying the brain tissue tracer concentrations of Evan's Blue by the method of optical pharmacokinetics. Optical measurements revealed that after intraarterial mannitol injection there was a progressive increase in tissue Evan's Blue concentrations and an increase in the brain:plasma Evan's Blue partition concentrations over time. These results suggest that, in the rabbit model, the BBB remains disrupted for an hour after intraarterial mannitol. The degree and duration of BBB disruption with intraarterial mannitol was also shown to be highly variable, as evidenced by a wide range of tissue Evan's Blue concentrations and brain:plasma partition coefficient. The variation was readily monitored by the optical measurements. In pre-clinical studies, optical quantification of BBB disruption could advance the understanding of drug delivery to the brain; and, during clinical procedures, feedback control of BBB disruption could increase the safety and efficacy of intraarterial mannitol, facilitating better control of delivery of chemotherapy agents to brain tissues.
